IVA vs. ACET, TELO, SKYE, GLSI, GOSS, OMER, SCPH, PRQR, AEON, and VERU
Should you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include Adicet Bio (ACET), Telomir Pharmaceuticals (TELO), Skye Bioscience (SKYE), Greenwich LifeSciences (GLSI), Gossamer Bio (GOSS), Omeros (OMER), scPharmaceuticals (SCPH), ProQR Therapeutics (PRQR), AEON Biopharma (AEON), and Veru (VERU). These companies are all part of the "pharmaceutical preparations" industry.
Inventiva (NASDAQ:IVA) and Adicet Bio (NASDAQ:ACET) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, community ranking, dividends and risk.
Inventiva has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Adicet Bio has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500.
Inventiva's return on equity of 0.00% beat Adicet Bio's return on equity.
In the previous week, Adicet Bio had 4 more articles in the media than Inventiva. MarketBeat recorded 6 mentions for Adicet Bio and 2 mentions for Inventiva. Adicet Bio's average media sentiment score of 0.14 beat Inventiva's score of 0.09 indicating that Adicet Bio is being referred to more favorably in the news media.
Adicet Bio received 270 more outperform votes than Inventiva when rated by MarketBeat users. However, 80.00% of users gave Inventiva an outperform vote while only 59.09% of users gave Adicet Bio an outperform vote.
Inventiva has higher earnings, but lower revenue than Adicet Bio.
Inventiva currently has a consensus price target of $17.00, suggesting a potential upside of 437.97%. Adicet Bio has a consensus price target of $12.83, suggesting a potential upside of 609.02%. Given Adicet Bio's higher probable upside, analysts clearly believe Adicet Bio is more favorable than Inventiva.
19.1% of Inventiva shares are owned by institutional investors. Comparatively, 83.9% of Adicet Bio shares are owned by institutional investors. 32.0% of Inventiva shares are owned by company insiders. Comparatively, 29.5% of Adicet Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Inventiva beats Adicet Bio on 8 of the 15 factors compared between the two stocks.
Get Inventiva News Delivered to You Automatically
Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inventiva Competitors List
Related Companies and Tools
